NIH initiative to balance sex of animals in preclinical studies: generative questions to guide policy, implementation, and metrics by McCullough, Louise D et al.
McCullough et al. Biology of Sex Differences 2014, 5:15
http://www.bsd-journal.com/content/5/1/15REVIEW Open AccessNIH initiative to balance sex of animals in
preclinical studies: generative questions to guide
policy, implementation, and metrics
Louise D McCullough1, Geert J de Vries2, Virginia M Miller3,4*, Jill B Becker5, Kathryn Sandberg6
and Margaret M McCarthy7Abstract
In May of 2014, the NIH Director together with the Director of the Office of Research on Women’s Health
announced plans to take a multi-dimensional approach to address the over reliance on male cells and animals
in preclinical research. The NIH is engaging the scientific community in the development of policies to improve
the sex balance in research. The present, past, and future presidents of the Organization for the Study of Sex
Differences, in order to encourage thoughtful discussion among scientists, pose a series of questions to generate
ideas in three areas: 1. research strategies, 2. educational strategies, and 3. strategies to monitor effectiveness
of policies to improve the sex balance in research. By promoting discussion within the scientific community, a
consensus will evolve that will move science forward in a productive and effective manner.
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Introduction
In May 2014, almost 20 years after the passing of the
NIH Revitalization Act requiring inclusion of women in
clinical research, NIH Director Francis S. Collins together
with Janine A. Clayton, Director of the Office of Research
on Women’s Health, announced NIH’s decision to address
the over-reliance on male cells and animals in preclinical
research [1]. This proposal arose from the realization
that translating male sex-biased preclinical research to
improvements in human health could result in adverse
consequences for women’s health and that taking sex
into account as a biological variable could improve repro-
ducibility of research results [2-5]. The agency plans to
take a multi-dimensional approach, which will include
development of new policies, with oversight by the
extramural research program [1]. One of the goals of
these plans is to increase the use of female cells and an-
imals in preclinical studies, thereby expanding the pool of* Correspondence: miller.virginia@mayo.edu
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article, unless otherwise stated.data derived from females. NIH is engaging the scientific
community in the development of these policies. The pur-
pose of this commentary is to stimulate a thoughtful dis-
cussion among scientists about this issue, first, by
posing a series of questions to generate ideas of various
strategies the NIH could use to improve the sex balance in
research, second, by suggesting ways to educate scientists
on concepts of sex and gender and ways to implement
those concepts into experimental design and, third, by
discussing mechanisms to monitor the effectiveness of
these strategies. It will be important that any new policy
maximizes limited resources without adding burdensome
regulations that hinder innovation. We note that there
is no one “right” answer to any of these questions and
that even the authors of this commentary at times disagree
on the best strategies and approaches to recommend.
However, we all agree that promoting discussion within
the scientific community will ultimately evolve to a
consensus that moves science forward in a productive
and effective manner.Rationale upon which to base policy: equity without equality
One way the NIH proposes to address the over-reliance
on male cells and animals in preclinical research is tontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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balance of male and female cells and animals in preclin-
ical studies in all future applications, unless sex-specific
inclusion is unwarranted, based on rigorously defined
exceptions [1]”.
Question #1: what would be reasonable exclusion criteria or
“defined exceptions?”
Discussion The answer is self-evident if one studies
sex-specific conditions like preeclampsia, which is a
condition of fulminating hypertension in pregnant women,
or function and diseases in organs present only in one
sex like the prostate and testes in men or the uterus
and ovaries in women. However, if one investigates a
condition that predominantly affects one sex, like breast
cancer, which is 100× more common in women than men,
does it make sense to include male animals or would this
also be considered a “rigorously defined exception?” If it is
an exception, would systemic lupus erythematosus, which
afflicts women 10:1 offer another exception? Or are these
two examples of where including males may identify
mechanisms that may be targets for new therapies to
reduce incidence or severity of these diseases in both
women and men? However, if these criteria do constitute
“exceptions”, then at what point would we determine that
sex imbalance in disease incidence would no longer
constitute reasonable grounds for exclusion of both sexes
in preclinical studies? And, is the sex ratio of disease inci-
dence the appropriate metric, or should it be based on the
sex ratio of disease severity, age of onset, and/or outcome?
Some diseases that occur less frequently in one sex than
another exhibit a worse outcome in the under-represented
sex, for example breast cancer in men, but is it because it
may go undiagnosed until a later stage or because there is
biological basis for a poor outcome?
Implementation Applications could require that the
investigator indicate if only one sex is being studied. If
this is the case, the reviewers could more carefully
examine the research design to determine if this is appro-
priate to the experimental design.
Question #2: who would determine that the sex-specific
inclusion criteria cited was unwarranted?
Discussion Could an NIH staff member exclude an
application before it reached the peer review panel? Or
would this decision be left to a peer review panel with
members that may or may not interpret the exclusion
criteria the way they were intended by NIH? If the panel
is not responsible for making this decision, would it fall
to programmatic review? If so, how would disputes over
this issue be resolved among principal investigators, peer
review panels, and program officers? Currently, once a
grant award is made, the principal investigator can modifythe direction but not the goal of the research to follow
their serendipitous discoveries to the benefit of biomedical
research.
Implementation A strategy to increase the use of females
in experiments which requires investigators to present
their plans for balancing male and female animals and
cells will be successful only if the experiments are actually
conducted and outcomes monitored.
Question #3: is the optimal approach to achieve equitable
sex balance in preclinical studies and in translating
preclinical research to improving human health through
policy change? If not, then what are the alternatives?
Discussion Another major goal of the new NIH policy
is to advance the translation of preclinical research to
improve men’s and women’s health. Some in the scientific
community say requiring investigators to study both
sexes in preclinical research would waste precious research
dollars. They argue that while many sex differences in
biology exist, most drugs are similarly effective in men and
women [6]. These observations suggest that physiological
and pharmacological mechanisms are shared between
males and females. Thus, conducting experiments in
both sexes may often result in unnecessary duplication
of data or data that provide limited added benefit to
our current state of knowledge. The doubling of cells
and animals will increase the costs not only of supplies
but also of personnel time and will slow down progress
due to the added workload.
Furthermore, some sex differences are species-specific
and irrelevant to the human condition. For example,
Drosophila represents a good species for studying some
basic biological phenomena but do not model vertebrate
sex differences. Other examples include hermaphroditic
species and birds, which have either no, or distinctly dif-
ferent, sex chromosome complement than mammalian
species.
On the other hand, an argument is made that we need
to understand the physiology and pathophysiology of the
female in the same detail as that of the male in order to
avoid costs associated with withdrawing drugs from the
market due to unforeseen adverse side effects in women.
It cannot be known a priori that drugs and even drugs
that are apparently efficacious in both females and males
are utilizing the same mechanisms or should be adminis-
tered in the same dosages [7]. Comparing disease causes
and treatments between the sexes in preclinical research
will lead to discovering novel drug targets [8]. Thus, how
can we afford not to study both sexes in a balanced way?
Who bears the responsibility for generating, maintaining,
and reporting the emerging data, which provide the
evidence upon which to develop sex-based diagnostic
and treatment algorithms? Should the responsibility
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individual investigator or at the level of grant review
panels (study section)? Would requiring individual investi-
gators to provide a rationale for why they were choosing
to study only one sex and not the other and making this
rationale a scorable peer review criterion raise awareness
in the individual and among scientific specialties? And if
so, would this awareness naturally lead to changes in
thinking that ultimately resulted in less reliance of one sex
over the other in future experimental design?
Implementation Some argue that requiring each investi-
gator to compare the sexes for at least one major compo-
nent of the proposed study is reasonable and would not
be overly burdensome. For example, if a proposal focuses
on mechanisms of hypertension, then at least one experi-
ment should compare the blood pressure in males and
females in the model of hypertension studied. Or if one
is studying mechanisms of alcohol addiction, at least
one experiment should be required to compare the level
of addiction between males and females in the model
investigated. Others are concerned that this minimal
requirement will not go far enough at balancing our
understanding of male and female physiology and patho-
physiology. However, uncovering substantial sex differences
should lead investigators and review panels to include and
require balances of sexes in subsequent experiments.
Would an alternative approach to achieving sex balance
in preclinical research at the level of the individual investi-
gator be to achieve this balance in aggregate across the
NIH research portfolio? In other words, the total NIH
budget for preclinical research would be spent equitably
on female and male cells and animals. If the premise is
that equity is achieved in total at NIH, the individual
investigator is not obligated to study both sexes, nor is
each program within each institute obliged to achieve a
50:50 split of research dollars spent on female and male
preclinical research. This model acknowledges that the
mission of some programs focuses on diseases that are
more prevalent in one sex than the other, and because of
these sex differences in incidence, it is not unreasonable
to hold a preclinical research portfolio that exhibits a bias
toward the over-represented sex.
How could NIH achieve this equity in preclinical research
overall? One answer proposed is that NIH could leverage
its existing chartered advisory committees including the
councils, which are required by law and are part of every
NIH institute. These advisory committees could develop
specific requests for application (RFAs) to address key areas
where data are deficient and thus encourage investigators
to venture into those areas. For example, there is a deficit
of research conducted in female models of chronic kidney
disease because most available models of kidney disease
exhibit little pathology in females. An RFA on mechanismsof chronic kidney disease in females would thus improve
the sex balance in renal disease research. This approach
would help to assure that the “best science” is funded.
However, would this approach give too much power to
program, and in so doing, erode the widely valued prin-
cipal among scientists of investigator-initiated research?
This equity in aggregate approach is conceptually similar
to Title IX, the federal civil rights law, which prohibits
sex discrimination in education. As the current pool of
investigators studying females is far smaller than those
studying male animals and cells, would this “Title IX”
approach to achieving a sex balance in preclinical research
[9] result in less competitive basic science grants being
funded at the expense of more competitive grants? Or
does “the best science” reflect the interdependency of
biomedical research in broadly related fields assuring
that the need to move forward in one field does not
end up limiting progress in another?
Education
Any multi-dimensional approach to increase the number
of female animals and cells in pre-clinical research
should also be accompanied by NIH-sponsored educational
initiatives. First and foremost, scientists need to be educated
on the use of the terms sex (biology: sex chromosomes,
hormones) and gender (psychosocial factors defining male
and female). Not all researchers need to become experts in
sex and gender biology or take a course in Sex Differences
101. However, all researchers should be aware that sex can
influence the outcome of their experiments and must be
accounted for as a critical biological variable. A question
such as “is a particular mechanism found in males the
same as it is in females?” is not the same as asking why
the mechanism may be the same or different, or when
and how sexual differentiation may occur. The NIH can
promote the concepts of sex as a biological variable and
the importance of sex differences and partner with
other government and private institutions to embed
these concepts into undergraduate and graduate science
and medical education. These educational efforts will
ensure that future scientists, review panels, and program
officers will not need specific training but instead consider
sex and gender within experimental design as “given.”
Several resources are available to assist researchers in
considering sex and gender in the design of their exper-
iments (see the succeeding lists). NIH should encourage
the expansion of these types of materials to meet the
needs of the next generation of researchers and facilitate
making such educational material readily accessible, e.g.,
online courses, webinars, and seminars. An easily access-
ible module on how to track the estrous cycle should
be part of this package although some resources for this
topic in rodents are already in the public domain [10].
A searchable catalog of reported sex differences in cells,
McCullough et al. Biology of Sex Differences 2014, 5:15 Page 4 of 7
http://www.bsd-journal.com/content/5/1/15tissues, genes, regulatory pathways, and behaviors is being
developed in the private sector but it is expensive to
develop and maintain (see the succeeding list).
The professional resources are as follows:
1. NIH funded Specialized Centers of Research on Sex
Differences
 Available at: http://orwh.od.nih.gov/
interdisciplinary/scor/index.asp
2. Textbooks
 Legato M. Principles of Gender-Specific
Medicine. Elsevier. 2011. 2nd ed.
 Oertelt-Prigione, Regitz-Zagrosek. Clinical Aspects
of Gender Specific Medicine. Springer. 2012
 Schenk-Gustafsson K, DeCola PR, Pfaff SW,
Plsetsky DS. Handbook of Clinical Gender
Medicine. Karger. 2012
 Regitz-Zagrosek, V. ed. Sex and Gender
Differences in Pharmacology. Springer-Verlag 2012
 Mattison, DR. ed. Clinical Pharmacology during
Pregnancy. Elsevier, 2013
3. Web-based continuing medicine education courses
 NIH ORWH Sex and Gender Differences in
Health and Behavior. Available at:
http://sexandgendercourse.od.nih.gov
 NIH ORWH The Basic Science and the Biological
Basis for Sex- and Gender-Related Differences.
Available at: http://sexandgendercourse.od.nih.gov
 TTUHSC Laura W. Bush Institute for Women’s
Health. “Y” Does “X” Make A Difference?
Available at: www.laurabushinstitute.org
 Women’s Health Info Site: Sex and Gender
Resource for Clinicians and Trainees. Available
at: http://whepducom.blogspot.com
 Resource listing of various educational modalities
to use in integration efforts. Available at:
http://www.drexelmed.edu/Home/OtherPrograms/
WomensHealthEducationProgram/Resources.aspx
4. Web-based research and educational resources
 Sex and Gender Women’s Health Collaborative.
Available at: www.sgwhc.org
 Stanford University’s Gendered Innovations.
Available at: http://genderedinnovations.stanford.
edu
 Canadian Institutes of Health Research. What a
Difference Sex and Gender Make in Health
Research. Available at: http://www.cihr-irsc.gc.ca/
e/44082.html
 NIH Office of Research on Women’s Health
Available at: http://orwh.od.nih.gov/sexinscience/
index.asp
5. Articles outlining experimental design methodology
 Becker JB, Arnold AP, Berkley KJ, Blaustein JD,
Eckel LA, Hampson E et al. Strategies andMethods for Research on Sex Differences in Brain
and Behavior. Endocrinology. 2005;146:1650–73
 Greenspan JD, Craft RM, LeResche L, Arendt-
Nielsen L, Berkley KJ, Fillingim RB et al. Studying
sex and gender differences in pain and analgesia:
A consensus report. Pain. 2007;132:S26-S45
 Miller VM, Kaplan JR, Schork NJ, Ouyang P,
Berga SL, Wenger NK et al. Strategies and
Methods to Study Sex Differences in
Cardiovascular Structure and Function: A Guide
for Basic Scientists. Biol Sex Differ. 2011;2:14.
doi:10.1186/2042-6410-2-14
 Shah K, McCormack CE, A BN. Do you know
the sex of your cells? Am J Physiol Cell Physiol.
2014;306:C3-C18
 Ritz SA, Antle DM, Cote J, et al. First steps for
integrating sex and gender considerations into
basic experimental biomedical research. FASEB
journal: official publication of the Federation of
American Societies for Experimental Biology
2014;28:4–13
6. Professional membership organizations
 Organization for the Study of Sex Differences.
Available at http://www.ossdweb.org
 International Society for Gender Medicine.
Available at http://www.isogem.com
7. Journals
 Biology of Sex Differences. Available at
http://www.bsd-journal.com
The tool box with suggestions to achieve sex balance
in preclinical studies modified from Figure Three of ref-
erence [11] is as follows:
1. Develop your knowledge of sex and gender
 Know the difference between sex and gender
 Avoid using the terms “sex” and “gender”
interchangeably
 Review the literature to determine if there are sex
or gender disparities for the phenomenon of
interest
2. Report and discuss
 Always report the sex of the cells, tissues,
animals, or participants you are studying.
 If there are data on both sexes, evaluate as such
and report the differences.
 Justify the use of only one sex and note the
limitations of this approach.
 Discuss the implications of sex and gender in
relationship to the results.
3. Educate others
 As a reviewer, ensure that grant proposals or
manuscripts:
a. Identify the sex of the experimental material
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c. Use the terms sex and gender appropriately.
 As a mentor and colleague, ask questions as to
whether sex and gender might be relevant to
their work?A second essential aspect of education promoted by the
NIH will be to help scientists overcome misconceptions
about using female animals. For example, a recent meta-
analysis found that in most studies, the variability in male
and female animals was comparable regardless of the stage
of the estrous cycle in females. A factor that added the
greatest variability to results was group housing males
and females [12]. Therefore, it will be important for
researchers to understand that hormonal variability
cannot be used as a justification for excluding female
animals from preclinical studies. The hormonal cycle
can be controlled for in the experimental design. This
concept needs to be understood by individual investiga-
tors, members of study section review committees, and
reviewers and editors for scientific publications to ensure
grant applications and papers that do not include females
because of the estrous cycle are appropriately critiqued.
Third and equally important, scientists need to under-
stand how to report results of sex differences without
bias. It is inaccurate to report a sex difference in response
as “better,” “improved,” or “worse” because this implies that
one sex is the norm while the other is the deviant. Rather,
sex differences should be reported objectively as “greater,”
“less,” “higher,” or “lower” in one sex than the other.
A fourth consideration is statistical power and the ability
to reliably detect or reject a sex difference in a given par-
ameter. This is not a simple matter of p values but instead
requires an accurate assessment of population variance,
with males and females included, in order to calculate
effect size (Cohen’s d). If an effect size is small (0.2 or less),
then even a statistically significant difference may not be
worth pursuing. Conversely, if an effect size is moderate
to large (0.5 or greater), then even marginally significant
probabilities might be of high biological significance. In
both cases, the critical variable is a sufficiently large
sample size to allow for a reliable estimate of population
variance. Individual investigators working in systems they
are familiar with should be able to predict the sample size
needed to achieve this goal. Thus, it would be unwise to
formulate policies that require the comparison of the two
sexes unless the comparison is sufficiently powered to
allow an evaluation whether the two sexes are different.
If sex differences are found, then the researchers should
discuss the implications of this observation with respect
to their overall study. For example, the mechanism of
action they studied may be relevant to only one sex.
Furthermore, their findings could warrant future research
designed to investigate how and why males and femalesdiffered in this parameter (i.e., studies of sex chromosomes,
gonadal hormones, and their interactions). Investigators
also should acknowledge that even if sex differences were
not observed in the one component of a system measured,
it is not accurate to conclude that all the other components
of this system are identical in females and males because
functional or behavioral outcomes that are similar in the
two sexes may be mediated by different fundamental mech-
anisms or may differ over the lifespan [13].
Lastly, even simple questionnaires can have an impact.
In 2009, the Canadian Institutes of Health Research (CIHR)
instituted a portfolio policy that required researchers to
address four questions related to sex and gender in all
grant applications (see the succeeding list) [14]. Similar
approaches have been developed by European agencies
[15]. Such questions require investigators to consider
their hypothesis in the context of human health and sex
disparities. Thoughtful answers to such questions help to
educate reviewers as to the significance of the proposed
project, and program officers could use the information
to better balance a portfolio of projects studying female
animals and sex differences. Critical to the usefulness of
this approach is to have the answers to such questions
become scorable review criterion.
The questions in grant applications submitted to the
Canadian Institutes of Research are as follows:
Questions
1. Are sex (biological) considerations taken into
account in this study? (Y/N)
2. Are gender (socio-cultural) considerations taken into
account in this study? (Y/N)
3. If YES, please describe how sex and/or gender
considerations will be considered in your research
design (maximum of 2,000 characters)
4. If NO, please explain why sex and/or gender are not
applicable in your research design (maximum of
2,000 characters)
Metrics and evaluation
Effectiveness of the new initiatives and policies in achiev-
ing the desired goal should be measurable. How then
should we measure increases in the knowledge base on
the biology of female animals and cells, increases in repro-
ducibility of scientific results, and reductions in disparities
in health outcomes between men and women?
Requiring a check box, filling in a chart, or answers to
questions may result in compliance to the form without
substantial change in practice, especially if the compli-
ance is without meaningful consequences. For example,
having investigators complete tables of numbers of male
and female animals to be used in experiments will only
affect the goals if the experiments are actually conducted
and the results are reported by sex.
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investigators to address issues of sex and gender in their
proposals, an audit of CIHR applications funded from
2010–2011 found an overall increase in the percentage of
researchers responding affirmatively to how their studies
accounted for sex and/or gender. However, the trend for
accounting for sex as an important biological variable
varied by discipline, by nature of the researchers (basic
versus clinical), and by sex of the researchers [14]. These
CIHR results can be used to inform development and
target groups for educational initiatives implemented
by NIH that are designed to educate scientists about
sex as a biological variable. Moreover, since the audit
included only funded applications, it is unclear how these
issues were considered overall by the scientific community
or how review committees considered answers to the
questions when deciding funding priorities.
Some practical steps to facilitate evaluation of the success
of the proposed policies would be to require including
the sex of the experimental material in the titles and
methods sections of all research articles, a policy already
implemented by several scientific journals [16,17]. This
reporting should be a requirement for research performed
with NIH funds and evaluated by study sections as part
of the standard review procedure. This should include
reporting sex differences in genetically modified species.
Listing papers published with grant support could be
accompanied by a field that would indicate sex of the
experimental material, numbers of males and females,
and results reported by sex. Such a system would track
outcomes from proposed work and provide an accessible
monitoring system. Progress reports could be evaluated
based on whether results collected included both sexes
as proposed and whether results are reported in
published papers for males and females separately.
However, study sections will need guidelines for evalu-
ation of progress reports and proposals. These steps
will make it possible to evaluate short-term progress
toward the goal. The long-term success will result only
from improved treatment guidelines and patient out-
comes with reduction in health disparities between
women and men.
Conclusions
The status quo is not a viable option
Numerous lines of evidence indicate that the current
status quo is not addressing fundamental issues of sex
differences that are evident in gene expression, regula-
tion of intracellular pathways, and disparities in health
outcomes. It is critical to stop the current lack of atten-
tion to the sex of animals and cells and the current bias
toward male subjects. A 2001 Institute of Medicine report
provided recommendations for, and identified barriers
to, advancing the science of sex differences, presentingseveral opportunities to advance science and medicine
(see the succeeding list) [18]. Scientists, educators, and
publishers were, and still are, in a position to implement
these recommendations without regulatory intervention.
However, because of the inertia and reticence among
these groups to consider and implement the Institute of
Medicine recommendations, here, we are 15 years later
with the potential for additional governmental regulatory
burden on the scientific enterprise.
The summary of recommendations from the Institute
of Medicine modified from the Executive Summary of the
Institute of Medicine report “Exploring the Biological
Contributions to Human Health: Does Sex Matter?” [18]
is as follows:
1. Recommendations for research
 Promote research on sex at the cellular level
 Study sex differences from womb to tomb
 Monitor sex differences and similarities for all
human diseases that affect both sexes
 Mine cross species information
 Investigate natural variation
2. Recommendations for overcoming barriers to
progress
 Clarity in the use of the terms sex and gender
 Determine and disclose the sex and hormonal
status of research material
 Make sex-specific data readily available and easily
accessible
 Support additional research, including
interdisciplinary research, on sex differences
 Conduct and construct longitudinal and clinical
studies so that results can be analyzed by sex
 Work to eliminate discrimination based on sex
differences
Thus, going forward, development of policies to address
deficiencies in our knowledge of sex and gender in bio-
logical mechanisms should encompass these areas: 1) at
the individual investigator level, appropriate rationale
for inclusion and exclusion for sex and gender in grant
applications, 2) at the programmatic level, accountability
for investigator rationale as part of scientific scoring of
projects and equity in portfolio management, 3) education
of researchers, grant reviewers, program officers, and
journal editors regarding evaluation and reporting of sex
and gender research, and 4) establishing clear measures
that will assess progress toward including sex and female
animals as critical variables in experimental design which
can be translated to improved health outcomes for women
and men. Cost analyses for implementation need to be
performed. Ease of participation and innovative educational
approaches to maximize compliance with defined goals
should be key drivers for program development. These
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among policy makers, scientists, and professional orga-
nizations to transform how science is done.
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